Compare iShares MSCI Taiwan ETF (EWT) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Taiwan ETF vs McKesson Corporation — how do they compare? iShares MSCI Taiwan ETF trades at $114.37 (market cap $12.74B), while McKesson Corporation trades at $937.1 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 8.5× iShares MSCI Taiwan ETF's market cap, and McKesson Corporation pays a 0.4% dividend while iShares MSCI Taiwan ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Taiwan ETF for 52 Days and McKesson Corporation for 74 Days on average.
| EWT | MCK | |
|---|---|---|
Market Cap | $12.74B | $108.46B |
Volume | 8,470,920 | 712,607 |
Sector | Broad Market / Factor | Health |
52-Week High | $118.00 | $995.69 |
52-Week Low | $60.03 | $725.17 |
Typical Hold Time | 52 Days | 74 Days |
Enterprise Value | — | $115.00B |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWT (iShares MSCI Taiwan ETF) trades at $114.16, down 1.79% on the day, with a bullish technical signal from moving averages while oscillators remain neutral. The ETF maintains strong exposure to Taiwan's semiconductor sector, particularly TSMC, benefiting from AI-driven demand. Recent news highlights Taiwan's strategic position in AI supply chains with companies planning significant US investments.
The outlook remains positive given Taiwan's dominance in semiconductor manufacturing and AI growth potential, though geopolitical risks and concentration in technology stocks present notable challenges. Institutional interest continues with Bank of America increasing its stake, supporting the ETF's long-term growth narrative despite near-term volatility.
McKesson Corporation (MCK) trades at $937.98, up 3.04% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent positive developments include the CVS Health partnership extension through 2032 and raised full-year guidance. Revenue growth remains robust at $359.05 billion for 2025, though net margins are thin at 1.12%.
The outlook remains positive with 81% analyst buy ratings and a $956.43 consensus target. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. Strong cash flow generation ($6.09B operating cash flow) supports the dividend and growth initiatives, while technical indicators show the stock testing resistance near $938.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
